Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.
Caroline Robert(Institut Gustave Roussy), Antoni Ribas(University of California, Los Angeles), Maxine Giannotti(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hassane M. Zarour(University of Pittsburgh), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Jeffrey S. Weber(NYU Langone Health), Jedd D. Wolchok(Cornell University), Peter Hersey(The University of Sydney), Richard Kefford(Broad Institute), Amita Patnaik(South Texas Accelerated Research Therapeutics), F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Xiaoyun Li(Nanjing University), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Tara C. Gangadhar(University of Pennsylvania), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 15
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k